Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Microbiota Alterations and Their Association With Oncogenomic Changes in Pancreatic Cancer Patients Publisher Pubmed



Sammallahti H1, 2 ; Kokkola A2 ; Rezasoltani S3 ; Ghanbari R4 ; Aghdaei HA5 ; Knuutila S1 ; Puolakkainen P2 ; Sarhadi VK6
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Pathology, Faculty of Medicine, University of Helsinki, Helsinki, 00014, Finland
  2. 2. Department of Surgery, Abdominal Center, Helsinki University Hospital and University of Helsinki, Helsinki, 00290, Finland
  3. 3. Foodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, P.O. Box 1985717411, Tehran, Iran
  4. 4. Digestive Oncology Research Center, Digestive Diseases Research Institute, Tehran University of Medical Science, P.O. Box 1411713135, Tehran, Iran
  5. 5. Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, P.O. Box 1985717411, Tehran, Iran
  6. 6. Department of Oral and Maxillofacial Diseases, Helsinki University Hospital and University of Helsinki, Helsinki, 00290, Finland

Source: International Journal of Molecular Sciences Published:2021


Abstract

Pancreatic cancer (PC) is an aggressive disease with a high mortality and poor prognosis. The human microbiome is a key factor in many malignancies, having the ability to alter host metabolism and immune responses and participate in tumorigenesis. Gut microbes have an influence on physiological functions of the healthy pancreas and are themselves controlled by pancreatic secretions. An altered oral microbiota may colonize the pancreas and cause local inflammation by the action of its metabolites, which may lead to carcinogenesis. The mechanisms behind dysbiosis and PC development are not completely clear. Herein, we review the complex interactions between PC tumorigenesis and the microbiota, and especially the question, whether and how an altered microbiota induces oncogenomic changes, or vice versa, whether cancer mutations have an impact on microbiota composition. In addition, the role of the microbiota in drug efficacy in PC chemo‐ and immunotherapies is discussed. Possible future scenarios are the intentional manipulation of the gut microbiota in combination with therapy or the utilization of microbial profiles for the noninvasive screening and monitoring of PC. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
Other Related Docs
11. Immunotherapy a New Hope for Cancer Treatment: A Review, Pakistan Journal of Biological Sciences (2018)
13. Pancreatic Cancer in Iran: An Epidemiological Review, Journal of Gastrointestinal Cancer (2020)
15. Cancer Nanomedicine: Special Focus on Cancer Immunotherapy, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)
27. Commercial and Regulatory Challenges in Cancer Nanomedicine, Functionalized Nanomaterials for Cancer Research: Applications in Treatments# Tools and Devices (2024)
34. Peptidomimetics in Cancer Targeting, Molecular Medicine (2022)
37. Immunology of Cutaneous Tumors and Immunotherapy for Melanoma, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2015)
40. Pancreatic Cancer Is Associated With Peripheral Leukocyte Oxidative Dna Damage, Asian Pacific Journal of Cancer Prevention (2017)
41. Anti-Cd20 Antibody Treatment for B-Cell Malignancies, Resistance to Anti-CD20 Antibodies and approaches for their Reversal: Volume 2 (2023)